

To: Minister van VWS[5.1.2e @minvws.nl]
 Cc: 5.1.2e 5.1.2e @modernatx.com] 5.1.2e 5.1.2e @modernatx.com] 5.1.2e
 5.1.2e 5.1.2e @modernatx.com]
 From: 5.1.2e
 Sent: Mon 8/23/2021 3:45:36 PM
 Subject: Moderna - Meeting Invite
 Received: Mon 8/23/2021 3:45:45 PM

Dear Minister De Jonge,

I hope this finds you well.

Since we last met on 7 June, Moderna has continued to work towards finding solutions to combat the COVID-19 pandemic. In particular, we have been focusing on developing a booster strategy that can tackle the existing and emerging variants as well as protect immunocompromised populations. If of interest, we would be delighted to meet with you and your team at a time of your convenience to discuss this in more detail.

Recent [study results](#) published in the *Journal Science* show that Spikevax maintains antibodies against the Alpha, Beta, Gamma, Delta, Epsilon and Iota variants to six months.

In addition to examining Spikevax's ability to combat variants, Moderna has also worked tirelessly on new solutions designed specifically against emerging variants. For example, in our Phase 2 studies we are currently examining a variant specific shot targeted at the Beta variant as well as a multivalent shot that contains our authorized Spikevax vaccine and our vaccine candidate targeted at the Beta variant.

With these developments in mind, we would welcome the opportunity to speak with you and your team to discuss how Moderna can support the on-going COVID-19 vaccination efforts in the Netherlands.

Please note that we also reached out to following stakeholders to discuss a potential meeting.

-
- 5.1.2e
- 5.1.2e
- 5.1.2e 5.1.2e
- 5.1.2e
- 5.1.2e

Thank you in advance for your time and consideration.

Kind regards,

5.1.2e

5.1.2e

5.1.2e

mobile: +41

5.1.2e

email: 5.1.2e @modernatx.com

modernatx.com

moderna



Confidentiality notice and disclaimer: The information in this message and any attachments is intended for the exclusive use of the addressee(s), is confidential and may be privileged or otherwise protected from disclosure. Any review, retransmission, dissemination or other use of, or taking of any action in reliance upon, of any such information by persons or entities other than the intended addressee(s) is prohibited. If you have received this message in error and are not the intended addressee, please notify the sender immediately and delete this message and any attachments from your system without reading or disclosing them. If you are not the intended addressee, be advised that any use of the information in this message and any attachment is prohibited and may be unlawful, and you must not copy this message or attachment or disclose the contents to any other person.